Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FSCN1 | Q16658 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | AHR | P35869 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | ACLY | P53396 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.46 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14341655 | 0.88 | SMN1; SMN2 (0.61) | FSCN1SMN1; SMN2ALDH1A1POLBRAB9A | |
| SCHEMBL12550518 | 0.84 | POLB (0.50) | FSCN1SMN1; SMN2ALDH1A1POLBRAB9A | |
| SCHEMBL692996 | 0.82 | ALDH1A1 (0.48) | SMN1; SMN2ALDH1A1POLBRAB9ANPC1 | |
| SCHEMBL2095575 | 0.82 | ALDH1A1 (0.48) | FSCN1SMN1; SMN2ALDH1A1POLBRAB9A | |
| SCHEMBL8986913 | 0.82 | ALDH1A1 (0.48) | FSCN1SMN1; SMN2ALDH1A1POLBRAB9A | |
| SCHEMBL12527997 | 0.81 | ALDH1A1 (0.56) | SMN1; SMN2ALDH1A1POLBRAB9ANPC1 | |
| SCHEMBL2392362 | 0.80 | ALDH1A1 (0.54) | FSCN1SMN1; SMN2ALDH1A1POLBRAB9A | |
| Hydrochloric Acid SCHEMBL11842627 | 0.80 | ALDH1A1 (0.47) | SMN1; SMN2ALDH1A1POLBRAB9ANPC1 | |
| SCHEMBL12435790 | 0.80 | ALDH1A1 (0.47) | FSCN1SMN1; SMN2ALDH1A1POLBRAB9A | |
| SCHEMBL7828029 | 0.80 | ALDH1A1 (0.47) | FSCN1SMN1; SMN2ALDH1A1POLBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005075471-A2 | THIAZOL-COMPOUNDS AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | BIOVITRUM AB (SE) | 2005-08-18 | — | — | WO | claimed |
| US-12351924-B2 | Electroreductive cross coupling | OHIO STATE INNOVATION FOUNDATION (US) | 2025-07-08 | — | — | US | disclosed |
| US-20230250539-A1 | ELECTROREDUCTIVE CROSS COUPLING | OHIO STATE INNOVATION FOUNDATION | 2023-08-10 | — | — | US | disclosed |
| CN-112851538-B | Method for promoting acylation of amine or alcohol by carbon dioxide | 中国科学院兰州化学物理研究所 | 2022-05-20 | — | — | CN | disclosed |
| US-20220098214-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING FIBROSIS | YALE UNIVERSITY | 2022-03-31 | — | — | US | disclosed |
| CN-112851538-A | Method for promoting acylation of amine or alcohol by carbon dioxide | 中国科学院兰州化学物理研究所 | 2021-05-28 | — | — | CN | disclosed |
| WO-2019016385-A1 | BENZAMIDE COMPOUNDS AND THEIR USE AS HERBICIDES | BASF SE (DE) | 2019-01-24 | — | — | WO | disclosed |
| WO-2017214505-A1 | CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| CN-103214329-B | Preparation method of N-methylformamide catalyzed by metallic copper salt | UNIV ZHEJIANG | 2014-12-10 | — | — | CN | disclosed |
| CN-103214329-A | Preparation method of N-methylformamide catalyzed by metallic copper salt | UNIV ZHEJIANG | 2013-07-24 | — | — | CN | disclosed |
| US-20110046336-A1 | TRANSITION METAL COMPLEX AND PROCESS FOR PRODUCING CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX | SUMITOMO CHEMICAL COMPANY, LIMITED | 2011-02-24 | — | — | US | disclosed |
| CN-101827854-A | Transition metal complex and method for producing conjugated aromatic compound using same | SUMITOMO CHEMICAL CO | 2010-09-08 | — | — | CN | disclosed |
| US-20100184978-A1 | BIPYRIDINE COMPOUND, TRANSITION METAL COMPLEX, AND METHOD FOR PRODUCTION OF CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-07-22 | — | — | US | disclosed |
| CN-101772508-A | Bipyridine compound, transition metal complex, and method for production of conjugated aromatic compound using the transition metal complex | SUMITOMO CHEMICAL CO | 2010-07-07 | — | — | CN | disclosed |
| EP-2192124-A1 | TRANSITION METAL COMPLEX AND PROCESS FOR PRODUCING CONJUGATED AROMATIC COMPOUND WITH THE TRANSITION METAL COMPLEX | Sumitomo Chemical Company, Limited (JP) | 2010-06-02 | — | — | EP | disclosed |
| EP-2172470-A1 | BIPYRIDINE COMPOUND, TRANSITION METAL COMPLEX, AND METHOD FOR PRODUCTION OF CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX | Sumitomo Chemical Company, Limited (JP) | 2010-04-07 | — | — | EP | disclosed |
| EP-0686636-B1 | TRICYCLIC BENZAZEPINE AND BENZOTHIAZEPINE DERIVATIVES | MEIJI SEIKA CO (JP) | 2001-04-04 | — | — | EP | disclosed |
| US-5840895-A | INTERMEDIATES FOR ANTIALLERGENS | MEIJI SEIKA KABUSHIKI KAISHA (JP) | 1998-11-24 | — | — | US | disclosed |
| US-5686442-A | ANTIALLERGENS | MEIJI SEIKA KABUSHIKI KAISHA (JP) | 1997-11-11 | — | — | US | disclosed |
| EP-0686636-A1 | TRICYCLIC BENZAZEPINE AND BENZOTHIAZEPINE DERIVATIVES | MEIJI SEIKA KABUSHIKI KAISHA (JP) | 1995-12-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046336-A1 | TRANSITION METAL COMPLEX AND PROCESS FOR PRODUCING CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX | C9, C5, AP1M1 | FSCN1 4488/4885SMN1; SMN2 3838/4885ALDH1A1 974/4885 |
| US-20100184978-A1 | BIPYRIDINE COMPOUND, TRANSITION METAL COMPLEX, AND METHOD FOR PRODUCTION OF CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX | C9, C5, AP2M1 | FSCN1 4703/4885SMN1; SMN2 4123/4885ALDH1A1 1092/4885 |
| US-20220098214-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING FIBROSIS | DUSP5, DUSP4, DUSP6 | FSCN1 943/4885SMN1; SMN2 3092/4885ALDH1A1 1762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.